Patents Assigned to Allergan, Inc.
  • Method of activating regulatory T cells with alpha-2B adrenergic receptor agonists
    Patent number: 10251865
    Abstract: Disclosed herein is a method of upregulating regulatory T-cells, and treating diseases that would benefit from such upregulation, by administering an alpha-2 receptor agonist.
    Type: Grant
    Filed: November 15, 2017
    Date of Patent: April 9, 2019
    Assignee: ALLERGAN, INC.
    Inventors: Daniel W. Gil, John E. Donello, Veena Viswanath, Lauren M. B. Luhrs
  • Botulinum toxin therapy for skin disorders
    Patent number: 10245305
    Abstract: Methods for treating skin disorders by local administration of a Clostridial toxin, such as a botulinum toxin, to a patient with a skin disorder.
    Type: Grant
    Filed: April 17, 2015
    Date of Patent: April 2, 2019
    Assignee: Allergan, Inc.
    Inventor: Eric R. First
  • Injection device
    Patent number: 10232129
    Abstract: An injection device includes a syringe having a body with a piston disposed therein with an open end along with a viscous fluid disposed in the body for injection by the piston. A needle assembly is provided which includes a cannula having a luer connection engageable with the syringe distal end with the luer connector including a hub. Mating engagement is provided by way of internal threads at the syringe distal end and external threads of a hub with a pitch sufficient to prevent detachment of the hub from the syringe distal end during ejection of the viscous fluid. In addition, a stepped cavity, disposed in the hub, further prevents detachment of the hub from the syringe distal end during ejection of the viscous fluid.
    Type: Grant
    Filed: December 2, 2009
    Date of Patent: March 19, 2019
    Assignee: Allergan, Inc.
    Inventors: Ahmet Tezel, Kevin McNerney, Christopher S. Mudd, Blake R. Storie, Bastien Mandaroux
  • Sustained drug delivery implant
    Patent number: 10231926
    Abstract: Biocompatible intraocular implants may include a brimonidine free base and a biodegradable polymer associated with the brimonidine free base to facilitate the release of the brimonidine free base into an eye with the polymer matrix lasts a period of time of not more than twice the drug release duration, but more than the drug release duration.
    Type: Grant
    Filed: November 14, 2016
    Date of Patent: March 19, 2019
    Assignee: Allergan, Inc.
    Inventors: Jane-Guo Shiah, Chetan Pujara
  • Devices for injection and dosing
    Patent number: 10226585
    Abstract: Injection devices are provided which include a handpiece capable of housing a cartridge containing an injectable composition, and a head coupled to the handpiece and housing a plurality of retractable needles and a dosing mechanism. Methods of treating skin surfaces are also provided.
    Type: Grant
    Filed: September 14, 2015
    Date of Patent: March 12, 2019
    Assignee: Allergan, Inc.
    Inventors: Ethan Franklin, Dimitrios Stroumpoulis, Zachary Dominguez, Justin Schwab, Bastien Mandaroux, Edwin Kayda
  • Compounds as tyrosine kinase modulators
    Patent number: 10221192
    Abstract: The present invention is directed to novel compounds of Formula I. The compounds of the present invention are potent tyrosine kinase modulators, and are suitable for the treatment and prevention of diseases and conditions related to abnormal activities of tyrosine kinase receptors.
    Type: Grant
    Filed: May 18, 2017
    Date of Patent: March 5, 2019
    Assignee: ALLERGAN, INC.
    Inventors: Xialing Guo, Zhen Zhu
  • Suture line administration technique using botulinum toxins
    Patent number: 10220079
    Abstract: The present invention utilizes patient-specific landmarks in order to treat headache pain. In one aspect, the present invention relates to the administration of Clostridial toxins, such as a botulinum neurotoxin, to a patient suffering from a headache pain, where the location of administration of the botulinum toxin is based upon at least one suture line of the patient's skull.
    Type: Grant
    Filed: November 27, 2017
    Date of Patent: March 5, 2019
    Assignee: Allergan, Inc.
    Inventor: Andrew M. Blumenfeld
  • Ophthalmic compositions and methods for treating eyes
    Patent number: 10213405
    Abstract: Ophthalmic compositions including compatible solute components and/or polyanionic components are useful in treating eyes, for example, to relieve dry eye syndrome, to protect the eyes against hypertonic insult and/or the adverse effects of cationic species on the ocular surfaces of eyes and/or to facilitate recovery from eye surgery.
    Type: Grant
    Filed: May 3, 2017
    Date of Patent: February 26, 2019
    Assignee: ALLERGAN, INC.
    Inventors: Joseph G. Vehige, Peter A. Simmons, Joan-En Chang-Lin
  • Preservative free brimonidine and timolol solutions
    Patent number: 10213431
    Abstract: The present invention is directed to preservative-free solutions of brimonidine and timolol for lowering intra-ocular pressure and treatment of glaucoma.
    Type: Grant
    Filed: July 28, 2011
    Date of Patent: February 26, 2019
    Assignee: Allergan, Inc.
    Inventors: Sukhon Likitlersuang, Ajay Parashar, Chetan P. Pujara, William F. Kelly
  • Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases
    Patent number: 10208071
    Abstract: The present invention relates to a method for treating ocular inflammatory diseases in a subject in need of such treatment, which comprises administering a pharmaceutical composition comprising a therapeutically effective amount of at least one agonist of Formyl peptide receptor 2.
    Type: Grant
    Filed: July 21, 2017
    Date of Patent: February 19, 2019
    Assignee: ALLERGAN, INC.
    Inventors: Richard L. Beard, John E. Donello, Veena Viswanath
  • Process for preparing metabolized conditioned growth media
    Patent number: 10206961
    Abstract: Compositions comprising metabolized conditioned growth medium and/or metabolized cell extract and methods of use are described. The metabolized conditioned growth medium and metabolized cell extract compositions may be formulated with an acceptable carrier into injectable or topical formulations, for example, as a cream, lotion or gel, and may be used in cosmeceutical or pharmaceutical applications. The metabolized conditioned growth medium and metabolized cell extract may also be further processed to concentrate or reduce one or more factors or components contained within the metabolized conditioned growth medium or metabolized cell extract. The growth medium may be conditioned by any eukaryotic cell. The metabolized conditioned growth medium and metabolized cell extract may be used to prevent or treat a condition, for example, a skin condition.
    Type: Grant
    Filed: October 7, 2013
    Date of Patent: February 19, 2019
    Assignee: Allergan, Inc.
    Inventors: James Vincent Gruber, Smitha Rao, Rahul Mehta, Sujatha D. Sonti
  • Suspensions of cyclosporin A form 2
    Patent number: 10206971
    Abstract: Disclosed herein are methods of formulating cyclosporin A Form 2.
    Type: Grant
    Filed: January 14, 2016
    Date of Patent: February 19, 2019
    Assignee: Allergan, Inc.
    Inventors: Anuradha V. Gore, Prem Swaroop Mohanty, E. Quinn Farnes
  • Implants and methods for treating inflammation-mediated conditions of the eye
    Patent number: 10206934
    Abstract: Methods for treating inflammation-mediated conditions of the eye are described, comprising: implanting into the vitreous of the eye of an individual a bioerodible implant comprising a steroidal anti-inflammatory agent and a bioerodible polymer, wherein the implant delivers the agent to the vitreous in an amount sufficient to reach a concentration equivalent to at least about 0.05 ?g/ml dexamethasone within about 48 hours and maintains a concentration equivalent to at least about 0.03 ?g/ml dexamethasone for at least about three weeks.
    Type: Grant
    Filed: October 2, 2017
    Date of Patent: February 19, 2019
    Assignee: Allergan, Inc.
    Inventors: Vernon G. Wong, Mae W. L. Hu
  • Pharmaceutical compositions comprising 7-(1H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
    Patent number: 10201535
    Abstract: The present invention relates to a method for treating skin diseases and skin conditions in a patient in need thereof which comprises of administering a therapeutically effective amount of a pharmaceutical composition comprising a therapeutically effective amount of 7-(1H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline, or its individual enantiomers or the tautomers thereof, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: March 13, 2017
    Date of Patent: February 12, 2019
    Assignee: ALLERGAN, INC.
    Inventors: Mohammed I. Dibas, Edward C. Hsia, John E. Donello, Daniel W. Gil
  • Sustained release intraocular implants and methods for treating ocular vasculopathies
    Patent number: 10201641
    Abstract: Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat one or more ocular conditions, such as an ocular vasculopathy or glaucoma, among others.
    Type: Grant
    Filed: October 19, 2015
    Date of Patent: February 12, 2019
    Assignee: Allergan, Inc.
    Inventors: Glenn T. Huang, Brittany Jackson, James A. Burke, Ton Lin, Patrick M. Hughes, Larry A. Wheeler, Rosy Sheng Donn
  • Method of enhancing hair growth
    Patent number: 10188591
    Abstract: Methods and compositions for stimulating the growth of hair are disclosed wherein said compositions include a cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl compound represented by the formula I wherein the dashed bonds represent a single or double bond which can be in the cis or trans configuration, A, B, Z, X, R1 and R2 are as defined in the specification. Such compositions are used in treating the skin or scalp of a human or non-human animal. Bimatoprost is preferred for this treatment.
    Type: Grant
    Filed: March 2, 2016
    Date of Patent: January 29, 2019
    Assignee: ALLERGAN, INC.
    Inventors: David F. Woodward, Amanda M. VanDenburgh
  • Pharmaceutical compositions and methods of use of 4-pregenen-11?-17-21-triol-3,20-dione derivatives
    Patent number: 10188667
    Abstract: The present invention relates to pharmaceutical compositions comprising 4-pregenen-11?-17-21-triol-3,20-dione derivatives, and their use as pharmaceuticals as modulators of the glucocorticoid receptors (GR) and/or the mineralocorticoid receptors (MR). The invention relates specifically to the use of these compounds and their pharmaceutical compositions to treat ocular conditions associated with the glucocorticoid receptors (GR) and/or the mineralocorticoid receptors (MR).
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: January 29, 2019
    Assignee: ALLERGAN, INC.
    Inventors: Jeffrey L. Edelman, Alissar Nehme
  • Ocular therapy using glucocorticoid derivatives selectively penetrating posterior segment tissues
    Patent number: 10188665
    Abstract: Ophthalmically therapeutic materials, such as liquid-containing compositions and polymeric drug delivery systems, include a therapeutic component that includes an Glucocorticoid Derivative which, upon delivery to the posterior segment of a mammalian eye, does not significantly diffuse to the anterior segment of said eye. Methods of making and using the present materials are also described.
    Type: Grant
    Filed: November 20, 2017
    Date of Patent: January 29, 2019
    Assignee: Allergan, Inc.
    Inventors: Jeffrey L. Edelman, Kelly M. Harrison
  • Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators
    Patent number: 10172832
    Abstract: The present invention relates to novel amide derivatives of N-urea substituted amino acids, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor like-1 (FPRL-1) receptor.
    Type: Grant
    Filed: April 10, 2018
    Date of Patent: January 8, 2019
    Assignee: ALLERGAN, INC.
    Inventors: Richard L. Beard, Tien T. Duong, John E. Donello, Veena Viswanath, Michael E. Garst
  • Method of enhancing hair growth
    Patent number: 10159631
    Abstract: Methods and compositions for stimulating the growth of hair are disclosed wherein said compositions include a cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl compound represented by the formula I wherein the dashed bonds represent a single or double bond which can be in the cis or trans configuration, A, B, Z, X, R1 and R2 are as defined in the specification. Such compositions are used in treating the skin or scalp of a human or non-human animal. Bimatoprost is preferred for this treatment.
    Type: Grant
    Filed: March 2, 2016
    Date of Patent: December 25, 2018
    Assignee: ALLERGAN, INC.
    Inventors: David F. Woodward, Amanda M. VanDenburgh